Latest Reimbursement News

EBR Systems has announced a fully underwritten A$55.9 million capital raise alongside a Security Purchase Plan to fund the commercial rollout of its FDA-approved WiSE CRT System, targeting a US$3.6 billion market opportunity in cardiac resynchronization therapy.

EBR Systems has raised A$55.9 million through a fully underwritten placement to fund the commercial rollout of its FDA-approved wireless cardiac pacing system, with plans for a limited market release in H2 2025 and expanded distribution in 2026.

Echo IQ’s application for a key US procedural code was rejected but the company plans a swift resubmission, maintaining confidence in its US commercial rollout.

Microba Life Sciences reveals breakthrough data showing its MetaPanel™ test detects elusive gastrointestinal pathogens in 20% of chronic cases, enabling targeted treatment and complete symptom resolution.

Gibb River Diamonds has inked a pivotal mining contract with BML Ventures to kickstart open pit gold mining at its Edjudina Project, aiming for production as early as August 2025.

High-Tech Metals has signed a joint venture with SSH Mining to drill, test, and sell historic low-grade gold stockpiles at Mt Fisher, aiming for early cash flow and project advancement.

Lumos Diagnostics has secured Medicare reimbursement for its FebriDx test from a fifth contractor, covering more than 70% of US Medicare payments and advancing its commercial reach.

Mineral Commodities Ltd reveals ongoing delays in completing the sale of its Skaland Graphite Project due to funding issues faced by the buyer, Norge Mineraler. Despite partial payments and new guarantees, the final USD 9.62 million payment remains outstanding.

EBR Systems has won FDA approval for its pioneering leadless WiSE CRT System, setting the stage for a phased US commercial rollout. The company also secured key Medicare reimbursement pathways and expanded manufacturing capacity, though financial sustainability remains a concern.

AVITA Medical reported a strong first quarter with revenues up 67% to $18.5 million, driven by expanded commercial sales and new product introductions. Despite a narrower net loss, the company faces ongoing challenges from revenue covenants and macroeconomic pressures.

AVITA Medical reveals a bold expansion plan targeting a $3.5 billion U.S. acute wound care market by 2025, driven by a multi-product portfolio and sustained revenue growth.

Echo IQ has raised $17.3 million through a strongly supported institutional placement to fund US commercialization and FDA approval efforts for its EchoSolv AI cardiology products.